These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 8692360)

  • 1. [Post-marketing surveillance].
    de Koning GH; Egberts AC; van Puijenbroek EP
    Ned Tijdschr Geneeskd; 1996 Jun; 140(22):1202. PubMed ID: 8692360
    [No Abstract]   [Full Text] [Related]  

  • 2. [Post-marketing surveillance].
    Offerhaus L
    Ned Tijdschr Geneeskd; 1996 Jun; 140(22):1201; author reply 1202. PubMed ID: 8692358
    [No Abstract]   [Full Text] [Related]  

  • 3. [The need for 'postmarketing surveillance'].
    Stricker BH; in 't Veld BA; Feenstra J
    Ned Tijdschr Geneeskd; 1999 Apr; 143(14):711-3. PubMed ID: 10347624
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety monitoring of new anti-malarials in immediate post-marketing phase.
    Edwards IR
    Med Trop (Mars); 1998; 58(3 Suppl):93-6. PubMed ID: 10212911
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Strategy for surveillance of adverse drug events.
    Bright RA
    Food Drug Law J; 2007; 62(3):605-16. PubMed ID: 17915403
    [No Abstract]   [Full Text] [Related]  

  • 6. [Importance and value of drug monitoring in medical practice].
    Schmitt J
    Bull Soc Sci Med Grand Duche Luxemb; 1995; 132(3):35-7. PubMed ID: 8665624
    [No Abstract]   [Full Text] [Related]  

  • 7. Post Launch Monitoring of food products: what can be learned from pharmacovigilance.
    van Puijenbroek EP; Hepburn PA; Herd TM; van Grootheest AC
    Regul Toxicol Pharmacol; 2007 Mar; 47(2):213-20. PubMed ID: 17204356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Post-marketing surveillance and adverse drug reactions.
    Shani S
    Isr Med Assoc J; 1999 Oct; 1(2):117-9. PubMed ID: 10731310
    [No Abstract]   [Full Text] [Related]  

  • 9. Adverse drug reaction monitoring in pediatric practice.
    Kshirsagar NA; Karande S
    Indian Pediatr; 1996 Dec; 33(12):993-8. PubMed ID: 9141798
    [No Abstract]   [Full Text] [Related]  

  • 10. Arthritis, Rheumatism and Aging Medical Information System Post-Marketing Surveillance Program.
    Singh G
    J Rheumatol; 2001 May; 28(5):1174-9. PubMed ID: 11361209
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The need for a post-marketing surveillance program in Israel.
    Shemer J
    Isr Med Assoc J; 1999 Oct; 1(2):98-9. PubMed ID: 10731306
    [No Abstract]   [Full Text] [Related]  

  • 12. Research methods in drug surveillance.
    Engel RR; Grohmann R; Rüther E; Hippius H
    Pharmacopsychiatry; 2004 Mar; 37 Suppl 1():S12-5. PubMed ID: 15052510
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decision support methods for the detection of adverse events in post-marketing data.
    Hauben M; Bate A
    Drug Discov Today; 2009 Apr; 14(7-8):343-57. PubMed ID: 19187799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pharmacovigilance: a case of phantom ships and Russian roulette].
    Stricker BH
    Ned Tijdschr Geneeskd; 2002 Jul; 146(27):1258-61. PubMed ID: 12138668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adverse drug reactions: a review of relevant factors.
    Ajayi FO; Sun H; Perry J
    J Clin Pharmacol; 2000 Oct; 40(10):1093-101. PubMed ID: 11028248
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Withdrawal of cerivastatin revealed a flaw of post-marketing surveillance system in the United States].
    Saito M; Hirata-Koizumi M; Miyake S; Hasegawa R
    Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2005; (123):41-5. PubMed ID: 16541751
    [TBL] [Abstract][Full Text] [Related]  

  • 17. European pharmacovigilance legislation: has it led to implementation of pharmacovigilance inspections?
    Bleumink GS; in't Veld BA; Stricker BH
    Pharmacoepidemiol Drug Saf; 2001; 10(4):339-40. PubMed ID: 11760496
    [No Abstract]   [Full Text] [Related]  

  • 18. [Post-marketing surveillance].
    Roos JC
    Ned Tijdschr Geneeskd; 1996 Mar; 140(11):620-1. PubMed ID: 8649530
    [No Abstract]   [Full Text] [Related]  

  • 19. Safety surveillance in drug development: understanding the process and its implications for nephrology nursing.
    Browar S
    Nephrol Nurs J; 2002 Apr; 29(2):143-50. PubMed ID: 11997949
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improving drug safety monitoring.
    Karande S; Gogtay NJ; Kshirsagar NA
    Indian Pediatr; 2003 Dec; 40(12):1167-75. PubMed ID: 14722367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.